Philadelphia / Mason / Nutley / New York / Bridgewater / /
Company
Glaxosmith kline Inc. / Rhone-Poulenc Rorer / Glaxosmithkline Inc. / Thomson Reuters / Roche / The Procter & Gamble Company / Merck / PROCTER & GAMBLE PHARMACEUTICALS INC. / Merrell Dow Inc. / HOFFMANN-LA ROCHE INC. / SmithKline Beecham Corp. / Merck & Co. / Johnson & Johnson / Aventis / Sanofi-Aventis U.S. LLC / Defendant Hoffmann-La Roche Inc. / Plaintiff Procter & Gamble Pharmaceuticals Inc. / Boniva / cham Corporation / Proctor & Gamble Pharmaceuticals Inc. / Glaxosmithkline plc / /
Continent
Europe / North America / /
Country
Australia / United Kingdom / United States / /
Currency
USD / BMD / /
Event
FDA Phase / /
Facility
Federal Judicial Center / /
IndustryTerm
treatment of a particular disease / phar maceutical products / compo site / advertising claims / particular site / skeletal site / healthcare providers / drug products / pharmaceutical product / treatment of osteoporosis / pharmaceutical and diagnostic products / healthcare / spe cific site / prevention of osteoporosis / placebo / corrective written statement / similar chemical qualities / pharmaceutical products / /
World Health Organization / Food and Drug Administration / United States District Court / Federal Judicial Center / UN Court / /
Person
John Bilezikian / Black / Lawrence M. Friedman / Salim Yusef / Fosomax / David H. Kaye / Marion Merrell Dow / Grauer / Chestnut Decl / David A. Freedman / Bile / /
Position
United States District Judge / researcher / Governor / leader / /